MAP2K7 and non-small cell lung carcinoma: Thus, a clinical trial is testing the efficacy and tolerability of the triple combination of the MEK inhibitor selumetinib, in continuous or intermittent dosing schedules, plus durvalumab, an anti-PD-L1, and tremelimumab, an anti-CTLA4, as antibodies in advanced or metastatic NSCLC patients (NCT03581487, Table 2) [128].